Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1585 to 1586 of 1586 entries
Sorted by: Best Match Show Resources per page
Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome.

Therapeutic drug monitoring

Koch BCP, Muller AE, Hunfeld NGM, de Winter BCM, Ewoldt TMJ, Abdulla A, Endeman H.
PMID: 34772892
Ther Drug Monit. 2022 Feb 01;44(1):11-18. doi: 10.1097/FTD.0000000000000942.

PURPOSE: Early initiation of antibiotics is essential for ameliorating infections in critically ill patients. The correct dosage of antibiotics is imperative to ensure their adequate exposure. Critically ill patients have altered pharmacokinetic parameters and are often infected by less...

Cite
Koch BCP, Muller AE, Hunfeld NGM, et al. Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome. Ther Drug Monit. 2022;44(1):11-18doi: 10.1097/FTD.0000000000000942.
Koch, B. C. P., Muller, A. E., Hunfeld, N. G. M., de Winter, B. C. M., Ewoldt, T. M. J., Abdulla, A., & Endeman, H. (2022). Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome. Therapeutic drug monitoring, 44(1), 11-18. https://doi.org/10.1097/FTD.0000000000000942
Koch, Birgit C P, et al. "Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome." Therapeutic drug monitoring vol. 44,1 (2022): 11-18. doi: https://doi.org/10.1097/FTD.0000000000000942
Koch BCP, Muller AE, Hunfeld NGM, de Winter BCM, Ewoldt TMJ, Abdulla A, Endeman H. Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome. Ther Drug Monit. 2022 Feb 01;44(1):11-18. doi: 10.1097/FTD.0000000000000942. PMID: 34772892.
Copy Download .nbib Format: NLM
Characterization of .

JAC-antimicrobial resistance

Sader HS, Mendes RE, Doyle TB, Davis AP, Castanheira M.
PMID: 34430873
JAC Antimicrob Resist. 2021 Aug 20;3(3):dlab136. doi: 10.1093/jacamr/dlab136. eCollection 2021 Sep.

OBJECTIVES: To evaluate the antimicrobial susceptibility and resistance mechanisms to β-lactams among METHODS: 2571 RESULTS: Overall susceptibility to ceftazidime and cefepime were 73.9% and 91.2% among CONCLUSIONS: Hyperproduction of chromosomal AmpC appears to be the most common mechanism of...

Cite
Sader HS, Mendes RE, Doyle TB, et al. Characterization of . JAC Antimicrob Resist. 2021;3(3):dlab136doi: 10.1093/jacamr/dlab136.
Sader, H. S., Mendes, R. E., Doyle, T. B., Davis, A. P., & Castanheira, M. (2021). Characterization of . JAC-antimicrobial resistance, 3(3), dlab136. https://doi.org/10.1093/jacamr/dlab136
Sader, Helio S, et al. "Characterization of ." JAC-antimicrobial resistance vol. 3,3 (2021): dlab136. doi: https://doi.org/10.1093/jacamr/dlab136
Sader HS, Mendes RE, Doyle TB, Davis AP, Castanheira M. Characterization of . JAC Antimicrob Resist. 2021 Aug 20;3(3):dlab136. doi: 10.1093/jacamr/dlab136. eCollection 2021 Sep. PMID: 34430873; PMCID: PMC8378278.
Copy Download .nbib Format: NLM
Showing 1585 to 1586 of 1586 entries